If you invest in the stock market, you must know the Glenmark Pharmaceuticals share price targets for 2026, 2027, 2028, 2029, 2030, 2040, and 2050. Here, you will get detailed information regarding all your queries, such as its fundamentals, shareholdings, financial performance, future predictions, and more.
Table of Contents
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals is a leading pharma company in India that makes affordable medicines for global markets. The company focuses on generic drugs, specialty medicines, and active pharma ingredients for better healthcare solutions. It operates in many countries and is known for strong research and development in dermatology, respiratory, and oncology products. Glenmark Pharmaceuticals is popular among investors searching for pharma stocks in India, best healthcare stocks, and long term growth stocks. The company aims to deliver high quality medicines while expanding its global presence and improving patient care.
Fundamental Analysis of Glenmark Pharmaceuticals
- Market Cap: ₹67,926 Cr.
- High / Low: ₹2,428 / ₹1,340
- Stock P/E: 25.1
- Book Value: ₹340
- Dividend Yield: 0.11%
- ROCE: 19.4%
- ROE: 15.8%
- Face Value: ₹1
Glenmark Pharmaceuticals Share Price Target 2026
After analysing past price trends and market performance, it is estimated that the Glenmark Pharmaceuticals stock price could reach a minimum of ₹2000 and potentially achieve a maximum target of ₹3000 in the year 2026.
Glenmark Pharmaceuticals Share Price Target 2027
After analysing past price trends and market performance, it is estimated that the Glenmark Pharmaceuticals stock price could reach a minimum of ₹2500 and potentially achieve a maximum target of ₹3500 in the year 2027.
Glenmark Pharmaceuticals Share Price Target 2028
After analysing past price trends and market performance, it is estimated that the Glenmark Pharmaceuticals stock price could reach a minimum of ₹3500 and potentially achieve a maximum target of ₹4500 in the year 2028.
Glenmark Pharmaceuticals Share Price Target 2029
After analysing past price trends and market performance, it is estimated that the Glenmark Pharmaceuticals stock price could reach a minimum of ₹4500 and potentially achieve a maximum target of ₹5500 in the year 2029.
Glenmark Pharmaceuticals Share Price Target 2030
After analysing past price trends and market performance, it is estimated that the Glenmark Pharmaceuticals stock price could reach a minimum of ₹5000 and potentially achieve a maximum target of ₹6000 in the year 2030.
Glenmark Pharmaceuticals Share Price Target 2040
After analysing past price trends and market performance, it is estimated that the Glenmark Pharmaceuticals stock price could reach a minimum of ₹13500 and potentially achieve a maximum target of ₹16500 in the year 2040.
Glenmark Pharmaceuticals Share Price Target 2050
After analysing past price trends and market performance, it is estimated that the Glenmark Pharmaceuticals stock price could reach a minimum of ₹27000 and potentially achieve a maximum target of ₹29000 in the year 2050.
Shareholding Pattern of Glenmark Pharmaceuticals
- Promoters: 46.65%
- Foreign Institutions: 20.34%
- Mutual Funds: 16.80%
- Retail and Others: 13.72%
- Other Domestic Institutions: 2.49%
Should You Invest in Glenmark Pharmaceuticals Stock?
| Year | Target Price (₹) |
|---|---|
| 2026 | 2000–3000 |
| 2027 | 2500–3500 |
| 2028 | 3500–4500 |
| 2029 | 4500–5500 |
| 2030 | 5000–6000 |
| 2040 | 13500–16500 |
| 2050 | 27000–29000 |
Whether you should invest or not, it depends on the many factors. Let us know the risk and opportunities to invest in Glenmark Pharmaceuticals stock.
Opportunities
- Strong presence in global pharma markets helps increase revenue growth and makes it a good pharma stock investment
- Focus on research and development supports new drug launches and long term business expansion
- Diverse product portfolio in generics and specialty medicines improves stability and growth potential
- Growing demand for affordable healthcare and medicines supports future earnings and stock growth
- Expansion in regulated markets like US and Europe attracts investors searching for best pharma stocks
Risks
- High competition in generic drug market can reduce pricing power and profit margins
- Regulatory approvals and strict compliance rules may delay product launches and impact revenue
- Dependence on key markets like US can create risk if demand or pricing changes
- Currency fluctuations can affect earnings from global operations and exports
- High research costs and failure of new drugs can impact profitability and investor confidence
Key Competitors of Glenmark Pharmaceuticals
Key competitors or peer companies of Glenmark Pharmaceuticals are Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Cipla, Lupin Limited, Aurobindo Pharma, Torrent Pharmaceuticals, Alkem Laboratories, Zydus Lifesciences, Biocon, and Divi’s Laboratories.
Disclaimer: All the information provided in this article is for educational purposes only. DateUpdateGo always advises seeking guidance from a certified financial advisor before making any investment-related decisions.
